COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2). First identified in Wuhan, China in December 2019, COVID-19 has since spread to become a global pandemic. In response to SARS-CoV-2 viral infection of the lungs, a cytokine storm can result. Acute or systemic inflammation results in fluid buildup in the lungs, respiratory distress, multiple organ failure, and can be fatal. We offer a wide array of MILLIPLEX® soluble protein panels and cell signaling kits to help elucidate the downstream signaling pathways when researching antiviral immune response. Our portfolio offers the widest range of analytes across the most species, including non-human primate panels for vaccine research.
Key Learnings:
- How MILLIPLEX® multiplex immunoassays can help you understand the immune response to SARS-CoV-2
- How to successfully integrate multiplex immunoassays into your disease research workflow
- How to generate the highest quality data using multiplex protein detection assays
For Research Use Only. Not For Use In Diagnostic Procedures.
Speaker
Brooke Gilliam
Merck
Global Product Manager, Immunoassay Platform Solutions
Brooke Gilliam is a Global Product Manager covering MILLIPLEX® panels. Prior to joining the Product Management team, Brooke managed the custom immunoassay R&D team and designed new immunoassay kits for protein biomarker detection. She earned her B.A. from Southern Illinois University in Carbondale, IL, USA and her M.S. from Saint Louis University in St. Louis, MO, USA.
Protein biology
- Protein quantitation
Durée:30min
Langue:English
Session 1:présenté(e) September 16, 2020
Pour continuer à lire, veuillez vous connecter à votre compte ou en créer un.
Vous n'avez pas de compte ?